Search
Otamixaban
go.drugbank.com/drugs/DB06635InvestigationalOtamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.
Categories: Heterocyclic Compounds, 1-RingDalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalDalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients.
Categories: Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: 4-AP, 4-AminopyridineDenosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigationalTwo denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia® … Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of
Products: XGEVA 120 MG SC. ENJEKSIYONLUK COZELTI ICEREN FLAKON, 4 ADET, XGEVA 120 MG SC. ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADETOfatumumab
go.drugbank.com/drugs/DB06650ApprovedInvestigationalOfatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. … [A6921] Ofatumumab is available for intravenous administration and is marketed as Arzerra.
Products: İNFÜZYONLUK ÇÖZELTİ KONSATRESİ İÇEREN FLAKON (3 ADET), İNFÜZYONLUK ÇÖZELTİ KONSATRESİ İÇEREN FLAKON (1 ADET)DiaPep 277
go.drugbank.com/drugs/DB06651InvestigationalDiaPep 277 is a 24-mer laboratory-made peptide derived from Hsp60(437-460).
Categories: Group I Chaperonins, Diabetes Mellitus, Type 1Saredutant
go.drugbank.com/drugs/DB06660InvestigationalSaredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Categories: Heterocyclic Compounds, 1-Ring, Receptors, Neurokinin-2, antagonists & inhibitorsOdanacatib
go.drugbank.com/drugs/DB06670InvestigationalOdanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesGimatecan
go.drugbank.com/drugs/DB06721InvestigationalGimatecan is an orally available 7-t-butoxyiminomethyl-substituted lipophilic camptothecin derivative.
Synonyms: (4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1-H-pyrano[3',4':6,7]-indolizino-[1,2-b]-quinoline-11-carbaldehyde O-(tert-butyl)-(E)-oxime, (4S)-11-[(E)-(tert-butoxyimino)methyl]-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione